Andrew R. Branagan

Hematology
55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Case 13-2026: A 76-Year-Old Woman with Fatigue, Rash, and Kidney Failure.

Case 13-2026: A 76-Year-Old Woman with Fatigue, Rash, and Kidney Failure.

Journal: The New England journal of medicine
Published: April 29, 2026

Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemia.

Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemia.

Journal: Leukemia & lymphoma
Published: January 22, 2026

WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

Journal: Blood cancer journal
Published: January 20, 2026

Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Journal: Leukemia
Published: November 13, 2025

Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

Journal: American journal of hematology
Published: November 10, 2025

Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Journal: Blood
Published: November 07, 2025

Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.

Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.

Journal: Blood
Published: November 07, 2025

Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Journal: Blood
Published: October 29, 2025

Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Journal: Blood
Published: October 29, 2025

Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

Journal: Blood cancer journal
Published: October 19, 2025

Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia.

Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia.

Journal: Blood advances
Published: September 30, 2025

Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom Macroglobulinemia.

Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom Macroglobulinemia.

Journal: Blood advances
Published: September 30, 2025
Showing 1-12 of 62

Last Updated: 09/26/2026